CLDN18 and gastric cancer: The CLDN18-ARHGAP fusion gene-derived neoantigen has good immunogenicity, and neoantigen-reactive T cells induced by it have specific and robust anti-tumor capacity both in in vitro coculture models and in vivo xenograft gastric cancer models.